Home > Boards > US OTC > Electronics and components >

Mosaic ImmunoEngineering Inc. (CPMV)

CPMV RSS Feed
Add CPMV Price Alert      Hide Sticky   Hide Intro
Moderator: MightySam
Search This Board: 
Last Post: 2/10/2021 8:04:48 PM - Followers: 258 - Board type: Free - Posts Today: 0

About the incoming Merging Entity - Mosaic ImmunoEngineering Inc. https://www.mosaicie.com/about


Current Programs


MOSAIC LEADERSHIPhttps://www.mosaicie.com/leadership


KEY PUBLICATIONS AND GRANTS - https://www.mosaicie.com/publications




MOSAIC ENGINEERING RECENT NEWS
 

Mosaic ImmunoEngineering Inc. signs license-option to advance novel immunotherapy to treat cancer and infectious diseases


https://thedaily.case.edu/mosaic-immunoengineering-inc-signs-license-option-to-advance-novel-immunotherapy-to-treat-cancer-and-infectious-diseases/

Agreement with CWRU Technology Transfer Office and Dartmouth College
Mosaic ImmunoEngineering Inc., a private biotechnology company based in Novato, California, has signed a two-year option agreement with Case Western Reserve University and Dartmouth College, granting the company the exclusive right to license technology for a novel platform technology using virus-like nanoparticles (“VLP”) to treat and prevent cancer and infectious diseases in humans and for veterinary use.

The technology has broad potential to treat many different types of cancer and is supported by numerous scientific publications and grant funding. The technology also has direct application as part of a vaccine platform, which has generated promising data in both cancer and infectious diseases, including COVID-19, through research funded by the National Science Foundation (NSF).

An option agreement provides Mosaic two years to obtain a full license agreement. A license option typically is granted to a company interested in further evaluation of the technology before entering into a full license agreement that allows the company to commercially market it. The two-year option to license agreement, is managed through Case Western Reserve’s Technology Transfer Office.

“Along with providing world-class research in many areas, Case Western Reserve University and Dartmouth College are striving to translate these exciting discoveries into products that can make a difference in the lives of patients with life threatening illnesses,” said Wayne Hawthorne, senior licensing manager in the university’s Technology Transfer Office. “We encourage our faculty to conduct basic research which can become the basis of discoveries that have direct application to clinical needs such as the technology that Mosaic is seeking to advance. Considerable research and progress was made on the technology through internal awards and grants that funded early product development and clinical proof from organizations such Coulter Foundation, Council to Advance Human Health and Ohio Third Frontier Technology Validation and Start-Up Fund.”

The inventors of the technology include Nicole Steinmetz, professor in the Department of NanoEngineering and director of the Center for Nano-ImmunoEngineering at the University of California San Diego (UCSD), and Jonathan Pokorski, associate professor in the Department of NanoEngineering at UCSD. During their tenure at Case Western Reserve, they worked in conjunction with Steven Fiering, a professor of microbiology and immunology at Dartmouth Geisel School of Medicine.

The researchers have collectively demonstrated that plant-derived, engineered VLP-based nanotechnologies stimulate a potent anti-tumor immune response in mouse models of metastatic melanoma, ovarian cancer, colon cancer, brain cancer and breast cancer, including companion dogs with metastatic melanoma. This data supports the potential to translate preclinical studies into veterinary applications, such as the treatment of cancer in companion animals, which has high relevance to human melanoma.

“We are pleased to have completed this agreement with CWRU and Dartmouth, and look forward to working closely with the university and Drs. Steinmetz, Pokorski and Fiering to rapidly advance the highly promising technology platforms into the clinic,” said Steven King, co-founder and chief executive officer of Mosaic. “This technology platform includes many opportunities in oncology and infectious diseases, including both human and veterinary applications. This is a very important milestone for Mosaic, and we are very happy to have the opportunity to work with prestigious universities and an impressive team of scientists.”

“This immuno-oncology approach provides a personalized treatment approach by relieving the patient’s tumor-mediated immunosuppression and potentiating anti-tumor immunity against antigens expressed by their own tumor,” said Steinmetz, a co-inventor of the technology and a co-founder and chief scientific officer of Mosaic. “The vaccine platform is a natural extension of the immune-stimulating properties of the VLP, combined with directing the response to pre-defined targets. Instead of being a personal vaccine, the modular approach of linking disease specific targets to the VLP allows the potential to rapidly develop countermeasures for pandemics such as COVID-19.”

Mosaic, through its founding team, has identified a lead oncology candidate for advancement into clinical trials and the ongoing NSF funded research is supporting the application of the technology toward the development of a SARS-CoV-2 vaccine for the prevention of COVID-19. Over the past 10 years, the technology has been funded through numerous research grants totaling more than $20 million.

For more information, contact Bill Lubinger at william.lubinger@case.edu.
CPMV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#22940  Sticky Note Nice news out!!! MightySam 08/31/20 12:14:42 PM
#23084   The small buys are simply manipulative to trick Neverending 02/10/21 08:04:48 PM
#23083   Thank you... 879k OS emit 02/10/21 03:34:46 PM
#23082   200.for.1 pre split adjusted the stock is at Neverending 02/08/21 06:44:49 PM
#23080   Yes. The move to the OTCQB is Prudent Capitalist 01/19/21 03:49:07 PM
#23079   Just saw news that the company is now potofgold 01/19/21 01:54:39 PM
#23078   USD 100 are possible in 2021 - CPMV Mountainman5 01/18/21 01:24:15 PM
#23077   The shares of CPMV should also be tradable Mountainman5 01/18/21 11:20:07 AM
#23076   NEWS, GOALS, COOPERATIONS, STRATEGIES and more are now Mountainman5 01/18/21 11:17:27 AM
#23075   ERIC LADER - a Scientist in JOE BIDEN`s Mountainman5 01/17/21 12:34:50 PM
#23074   What kind.of fool.would.get taken by these guys AGAIN! Neverending 01/13/21 07:02:20 PM
#23073   Yes 500 to 1 MightySam 01/13/21 08:42:30 AM
#23072   Hope this is what you are looking for - MightySam 01/12/21 07:47:03 PM
#23071   Ok, can someone point me to the FIRNA/8K emit 01/10/21 12:41:26 AM
#23070   Sad sucker peeps.The CEO touted positive results at Neverending 01/04/21 05:21:36 PM
#23069   ok. Good. Thanks. EOM. potofgold 01/04/21 02:18:41 PM
#23068   We should start getting updates on their cancer MightySam 01/04/21 02:12:44 PM
#23067   NOW. Let's get that volume up. Don't know potofgold 01/04/21 01:22:39 PM
#23066   We got our new symbol. Progress MightySam 12/31/20 09:08:38 AM
#23065   ok. good, That's what I initially thought but potofgold 12/30/20 11:48:45 AM
#23064   Effective Dec. 31,2020 PTSCD will change to CPMV: Renee 12/30/20 09:20:31 AM
#23063   Boy this thing is going the wrong direction...someone Ubgood 12/28/20 06:45:38 PM
#23062   We're getting our new ticker symbol this Wednesday potofgold 12/28/20 12:25:12 PM
#23061   Total correct...all we need is to bring back Ubgood 12/26/20 07:15:22 AM
#23060   Sucker.investor trifecta:EDIG, PTSC and PPHM! Soon to include Neverending 12/15/20 05:13:24 PM
#23059   SELL THE POP! You.know.they are cooking up some Neverending 12/15/20 09:27:30 AM
#23058   Even.if.CEO Steve King announces.great.drug trial results BEWARE!>>> Neverending 12/15/20 08:53:27 AM
#23057   Yes, the D and symbol change should be MightySam 12/14/20 03:43:25 PM
#23056   They are "flim-flam"artists.They take a kernel of truth Neverending 12/14/20 03:28:27 PM
#23055   news link: https://ca.finance.yahoo.com/news/mosaic-immunoengineering-inc-provid potofgold 12/14/20 11:01:15 AM
#23054   I encourage everyone that invests in this company bfiest 12/14/20 09:03:07 AM
#23053   Retarded?? Ubgood 12/09/20 07:49:26 PM
#23052   Income? I dont believe.they.are.selling anything! Some "folks" are Neverending 12/09/20 07:19:28 PM
#23051   Many.suckers left! We will make.a.lot of money off Neverending 12/09/20 07:15:45 PM
#23050   Probably not. Would have to hire one. I potofgold 12/09/20 12:07:02 PM
#23049   That's on low volume...wait to see what happens Ubgood 12/09/20 12:00:56 PM
#23048   and there it is. Was beginning to think potofgold 12/09/20 11:56:55 AM
#23047   and that's the end of this month right? eom. potofgold 12/08/20 01:44:13 PM
#23046   The real run starts once we get the MightySam 12/08/20 11:22:39 AM
#23045   she's sliding. Still nice to see it get potofgold 12/07/20 12:27:27 PM
#23044   Just got to say this is nice to see. potofgold 12/07/20 11:29:37 AM
#23043   Your New CEO, Steven King, was up for Neverending 12/06/20 10:52:27 AM
#23042   Let's see where it trades starting tomorrow under Prudent Capitalist 12/02/20 05:21:02 PM
#23041   It's a scam...question is can you make any Ubgood 12/02/20 04:34:16 PM
#23040   TD Ameritrade even hit me with a $38 Prudent Capitalist 12/02/20 12:43:50 PM
#23039   No one is going to buy this trash...better Ubgood 12/02/20 12:35:11 PM
#23038   WOW! Didn't see that typo. What I was potofgold 12/02/20 09:54:52 AM
#23037   Wasn't expecting to be what it's going to potofgold 12/02/20 09:02:59 AM
#23036   Patriot Scientific Corp. changed to Mosaic ImmunoEngineering Inc. Renee 12/01/20 07:14:04 PM
#23035   November quarter end has come. Let's see what potofgold 12/01/20 02:17:04 PM
#23034   Same scam as before..pohl and carlton moved to Ubgood 11/27/20 06:37:12 PM
PostSubject
Consent Preferences